Ocular Therapeutix Showcases Innovations at Industry Meetings
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to improving vision through innovative therapies targeting retinal diseases and other eye conditions. With a strong commitment to enhancing patient outcomes, Ocular Therapeutix is set to participate in multiple panels and presentations at various ophthalmology meetings in October 2024, specifically highlighting advancements in retinal therapeutics.
Upcoming Ophthalmology Meetings
During October 2024, Ocular Therapeutix will be actively participating in three significant ophthalmology gatherings. These events include key presentations and panel discussions that will feature the insights of leading experts in the field.
Eyecelerator at AAO 2024
The first event Ocular Therapeutix will attend is the Eyecelerator session at the American Academy of Ophthalmology (AAO) 2024 conference. Scheduled for October 17, the company will present a panel titled "Fueling Progress: The Power of Innovation and Perseverance," featuring Pravin U. Dugel, MD, the Executive Chair, President, and CEO. This panel discussion will take place from 10:00 to 11:00 AM CT.
Company Presentation on Retinal Focus
On the same day, Ocular Therapeutix will deliver a crucial presentation on its transformation into a company focused on retinal therapies. The session, titled "Ocular Therapeutix: Transformation Into A Retina-focused Company," will occur during the Retina Showcase at 1:24 PM CT, where Peter K. Kaiser, MD, Chief Development Officer, will present insights into the company's strategic advancements.
Participation in Innovate RETINA 2024
Following the Eyecelerator session, Ocular Therapeutix will also be represented at Innovate RETINA 2024, where it will take part in another panel discussion titled "The Future of Retinal Therapeutics." This session is planned for the evening of October 17 at 6:30 PM CT, again featuring Dr. Dugel.
American Academy of Ophthalmology Conference
The AAO conference, running from October 18 to 21, will also provide Ocular Therapeutix with an excellent platform to showcase their research. Among the highlights is poster presentation scheduled for the conference on the sustained efficacy of OTX-TKI in the treatment of nAMD, presented by David A. Eichenbaum, MD, FASRS. Ocular Therapeutix encourages those interested to find a full copy of the poster on their official website under the "Investors" section.
About Ocular Therapeutix
Ocular Therapeutix is recognized for its innovative approach to ocular therapies, particularly through its proprietary ELUTYX technology, which is pivotal to its flagship product candidate AXPAXLI (OTX-TKI). This product is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration. Furthermore, the company’s pipeline includes significant products like DEXTENZA, an FDA-approved solution for ocular inflammation, and PAXTRAVA, which addresses glaucoma and ocular hypertension.
Ocular Therapeutix remains committed to enhancing the quality of life for patients through rigorous scientific exploration and product development, utilizing the latest technological advancements in the field.
Contact Information
For media and investor inquiries, Ocular Therapeutix can be contacted via:
Bill Slattery
Vice President, Investor Relations
Email: bslattery@ocutx.com
Frequently Asked Questions
What is Ocular Therapeutix focused on?
Ocular Therapeutix is dedicated to developing innovative therapies for retinal diseases and enhancing overall vision health.
When will Ocular Therapeutix present at the AAO conference?
Ocular Therapeutix will present at the AAO conference from October 18 to 21, with multiple sessions on October 17.
Who are the key presenters for Ocular Therapeutix?
Key presenters include Pravin U. Dugel, MD, and Peter K. Kaiser, MD, showcasing their expertise in retinal therapeutics.
What is AXPAXLI used for?
AXPAXLI is an investigational product intended for the treatment of wet age-related macular degeneration (wet AMD).
Where can one find more information about Ocular Therapeutix's presentations?
More details and copies of presentations are available on the Ocular Therapeutix website under the "Investors" page.
